Annual Notice to Physicians

19 July 2021

Dear Northern Light Laboratory Client:

The Office of the Inspector General (OIG), in its Guidance for Clinical Laboratories, believes that labs are in a unique position to be able to educate their clients by providing annual written notice with the following important information:

  • Organ or disease related panels will only be paid when all components are medically necessary;

  • The OIG takes the position that an individual who knowingly causes a false claim to be submitted may be subject to sanctions or remedies available under civil, criminal, and administrative law;

  • Medicaid reimbursement amounts will be equal to or less than the amount of Medicare reimbursement. A link to the 2016 Clinical Laboratory Fee Schedule (in both CSV and Excel formats) can be found by visiting this URL:

  • Using a customized profile may result in the ordering of tests which are not reasonable or necessary and will not be covered by Medicare;

  • Medicare coverage is limited to items and services that are reasonable and necessary for the diagnosis or treatment of an illness or injury and are within the scope of a Medicare benefit category. National coverage determinations (NCDs) are made through an evidence-based process, with opportunities for public participation. In the absence of a national coverage policy, an item or service may be covered based on a local coverage determination (LCD). All test orders that do not satisfy NCD or LCD medical necessity guidelines must be accompanied by a properly executed Advance Beneficiary Notice (ABN). Links to the current National and Local Coverage Determinations can be found at the following websites:

Lab National Coverage Determinations (NCDs) Alphabetical Index:

Lab Local Coverage Determinations (LCDs) Alphabetical Index (enter as a guest doing business in Maine/select Medical Policy & Review/Medical Policy Center/View a list of active LCDs for your region):

  • Heavy Metals LCD

  • Federal law requires that a clinical consultant be available in all clinical laboratories.  If you have any questions regarding the appropriate choice of lab tests or need consultation, please call Orin W. Buetens, MD, Medical Director at (207) 973-7617.

Should you have any questions or need additional information regarding lab testing, please call Jen Long, NLL Client Support Representative, at (207) 944-9970.  For compliance questions or concerns, please call me at (207) 973-7649.

Kind regards,
Dayna M. Emerson MS, RD, LD, CHC, CACO
Compliance & Privacy Officer
Compliance & Internal Audit
Northern Light Laboratory
Direct: 207-973-7649
Medicare National Coverage Determinations (NCD) and Applicable ALI Test Options
Alpha-fetoprotein AFP
Blood Counts CBC
Blood Glucose Testing GLU
Carcinoembryonic Antigen CEA
Collagen Crosslinks, any Method NTX
Digoxin Therapeutic Drug Assay DIGO
Fecal Occult Blood Test Occult Blood
Gamma Glutamyl Transferase GGT
Glycated Hemoglobin/Glycated Protein HGBAG
Hepatitis Panel/Acute Hepatitis Panel HEP 1
Human Chorionic Gonadotropin BHGC
Human Immunodeficiency Virus (HIV) Testing (Diagnosis) HIV  
Human Immunodeficiency Virus (HIV) Testing (Prognosis Including Monitoring) HIVPCRQ
Lipid Testing HDL 2
Partial Thromboplastin Time (PTT) PTT
Prostate Specific Antigen PSA
Prothrombin Time (PT) PT/INR
Serum Iron Studies IRON
Thyroid Testing TSH
T3 or T4 update
T4, free
Tumor Antigen by Immunoassay - CA 125 CA125
Tumor Antigen by Immunoassay - CA 15-3/CA 27.29 CA153
CA 27 29
Tumor Antigen by Immunoassay - CA 19-9 CA199
Urine Culture, Bacterial C URINE
Medicare Local Coverage Determinations (LCD) and Applicable ALI Test Options
B-type Natriuretic Peptide (BNP) Testing PROBNP
RAST Type Tests IGE
Allergy testing
Urine Drug Testing (as of 12/01/15) UDR
Vitamin D Assay Testing VIT D 25